World's Best Scientists 2026 revealed!
Award Badge
Immunology
USA
2026

D-Index & Metrics

Immunology

D-Index
163
Citations
102518
World Ranking
70
National Ranking
48

Medicine

D-Index
163
Citations
102518
World Ranking
685
National Ranking
395

John R. Mascola publication distribution in Immunology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Immunology in 2026. The highlighted bar marks where John R. Mascola sits on this spectrum.

62–71 publications: 9 scientists 72–81 publications: 23 scientists 82–91 publications: 40 scientists 92–101 publications: 72 scientists 102–111 publications: 86 scientists 112–121 publications: 108 scientists 122–131 publications: 150 scientists 132–141 publications: 160 scientists 142–151 publications: 159 scientists 152–161 publications: 189 scientists 162–171 publications: 166 scientists 172–181 publications: 181 scientists 182–191 publications: 188 scientists 192–201 publications: 187 scientists 202–211 publications: 178 scientists 212–221 publications: 158 scientists 222–231 publications: 168 scientists 232–241 publications: 159 scientists 242–251 publications: 160 scientists 252–261 publications: 148 scientists 262–271 publications: 116 scientists 272–281 publications: 125 scientists 282–291 publications: 115 scientists 292–301 publications: 111 scientists 302–311 publications: 95 scientists 312–321 publications: 97 scientists 322–331 publications: 97 scientists 332–341 publications: 99 scientists 342–351 publications: 96 scientists 352–361 publications: 68 scientists 362–371 publications: 76 scientists 372–381 publications: 71 scientists 382–391 publications: 71 scientists 392–401 publications: 62 scientists 402–411 publications: 54 scientists 412–421 publications: 41 scientists 422–431 publications: 63 scientists 432–441 publications: 53 scientists 442–451 publications: 31 scientists 452–461 publications: 42 scientists 462–471 publications: 40 scientists 472–481 publications: 29 scientists 482–491 publications: 34 scientists 492–501 publications: 30 scientists 502–511 publications: 23 scientists 512–521 publications: 41 scientists 522–531 publications: 29 scientists 532–541 publications: 28 scientists 542–551 publications: 16 scientists 552–561 publications: 18 scientists 562–571 publications: 18 scientists 572–581 publications: 17 scientists 582–591 publications: 17 scientists 592–601 publications: 17 scientists 602–611 publications: 19 scientists 612–621 publications: 13 scientists 622–631 publications: 12 scientists 632–641 publications: 11 scientists 642–651 publications: 16 scientists 652–661 publications: 9 scientists 662–671 publications: 5 scientists 672–681 publications: 13 scientists 682–691 publications: 12 scientists 692–701 publications: 6 scientists 702–711 publications: 6 scientists 712–721 publications: 9 scientists 722–731 publications: 9 scientists 732–741 publications: 6 scientists 742–751 publications: 11 scientists 752–761 publications: 10 scientists 762–771 publications: 7 scientists 772–781 publications: 12 scientists 782–791 publications: 7 scientists 792–801 publications: 5 scientists 802–806 publications: 1 scientists 807+ publications: 100 scientists
62 publications 807+

This scientist: 638 publications — 95th percentile

95% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 807 publications or more.

John R. Mascola D-index placement in Immunology in 2026

The chart shows the D-index (discipline H-index) distribution of Immunology scientists ranked by Research.com in 2026. The highlighted bar marks where John R. Mascola sits on this spectrum.

40–41 D-Index: 28 scientists 42–43 D-Index: 91 scientists 44–45 D-Index: 157 scientists 46–47 D-Index: 192 scientists 48–49 D-Index: 175 scientists 50–51 D-Index: 188 scientists 52–53 D-Index: 177 scientists 54–55 D-Index: 155 scientists 56–57 D-Index: 194 scientists 58–59 D-Index: 201 scientists 60–61 D-Index: 197 scientists 62–63 D-Index: 201 scientists 64–65 D-Index: 173 scientists 66–67 D-Index: 167 scientists 68–69 D-Index: 172 scientists 70–71 D-Index: 199 scientists 72–73 D-Index: 184 scientists 74–75 D-Index: 133 scientists 76–77 D-Index: 162 scientists 78–79 D-Index: 127 scientists 80–81 D-Index: 121 scientists 82–83 D-Index: 125 scientists 84–85 D-Index: 121 scientists 86–87 D-Index: 102 scientists 88–89 D-Index: 96 scientists 90–91 D-Index: 75 scientists 92–93 D-Index: 72 scientists 94–95 D-Index: 74 scientists 96–97 D-Index: 66 scientists 98–99 D-Index: 68 scientists 100–101 D-Index: 49 scientists 102–103 D-Index: 60 scientists 104–105 D-Index: 54 scientists 106–107 D-Index: 36 scientists 108–109 D-Index: 23 scientists 110–111 D-Index: 52 scientists 112–113 D-Index: 41 scientists 114–115 D-Index: 34 scientists 116–117 D-Index: 25 scientists 118–119 D-Index: 28 scientists 120–121 D-Index: 11 scientists 122–123 D-Index: 20 scientists 124–125 D-Index: 27 scientists 126–127 D-Index: 19 scientists 128–129 D-Index: 20 scientists 130–131 D-Index: 16 scientists 132–133 D-Index: 17 scientists 134–135 D-Index: 14 scientists 136–137 D-Index: 15 scientists 138–139 D-Index: 9 scientists 140–141 D-Index: 11 scientists 142–143 D-Index: 9 scientists 144–145 D-Index: 9 scientists 146–147 D-Index: 7 scientists 148–149 D-Index: 7 scientists 150–151 D-Index: 7 scientists 152–153 D-Index: 5 scientists 154–155 D-Index: 8 scientists 156 D-Index: 6 scientists 157+ D-Index: 96 scientists
40 D-Index 157+

This scientist: 163 D-Index — 99th percentile

99% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 157 D-Index or more.

Research.com Recognitions

  • 2026 - Research.com Immunology in United States Leader Award
  • 2025 - Research.com Immunology in United States Leader Award
  • 2017 - Member of the National Academy of Medicine (NAM)
  • Member of the Association of American Physicians
  • Member of the Association of American Physicians
  • Member of the Association of American Physicians
  • Member of the Association of American Physicians

Overview

John R. Mascola is affiliated with ModeX Therapeutics in the United States and has contributed extensively to research in medicine, immunology, and microbiology. Their work spans multiple subfields including infectious diseases, virology, immunology, epidemiology, and radiology, nuclear medicine, and imaging.

The scientist's research covers a range of main topics such as HIV research and treatment, SARS-CoV-2 and COVID-19 research, monoclonal and polyclonal antibodies research, HIV/AIDS drug development and treatment, immune cell function and interaction, viral gastroenteritis research and epidemiology, and studies on animal virus infections.

Frequently publishing in venues recognized in the scientific community, John R. Mascola has contributed to:

  • bioRxiv (Cold Spring Harbor Laboratory)
  • UNC Libraries
  • Science Translational Medicine
  • Cell Reports
  • Nature Communications

Their collaborative work includes frequent co-authorship with researchers such as Peter D. Kwong, Barney S. Graham, Nicole A. Doria-Rose, Tongqing Zhou, and Adrian B. McDermott.

Notable recent publications include:

  • An mRNA Vaccine against SARS-CoV-2 - Preliminary Report, 2020, New England Journal of Medicine
  • SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness, 2020, Nature
  • Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates, 2020, New England Journal of Medicine
  • Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination, 2020, New England Journal of Medicine
  • Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19, 2021, New England Journal of Medicine

John R. Mascola has been recognized with memberships in professional organizations including the National Academy of Medicine (NAM) since 2017 and the Association of American Physicians.

Best Publications

  • Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine.

    Lindsey R. Baden;Hana M El Sahly;Brandon J Essink;Karen Kotloff

  • An mRNA Vaccine against SARS-CoV-2 — Preliminary Report

    Lisa A. Jackson;Evan J. Anderson;Nadine G. Rouphael;Paul C. Roberts

  • Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7.

    Pengfei Wang;Manoj S. Nair;Lihong Liu;Sho Iketani;Sho Iketani

  • Rational Design of Envelope Identifies Broadly Neutralizing Human Monoclonal Antibodies to HIV-1

    Xueling Wu;Zhi Yong Yang;Yuxing Li;Carl Magnus Hogerkorp

  • Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies

    John R. Mascola;Gabriela Stiegler;Thomas C. VanCott;Hermann Katinger

  • SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness.

    Kizzmekia S. Corbett;Darin K. Edwards;Sarah R. Leist;Olubukola M. Abiona

  • Structural basis for broad and potent neutralization of HIV-1 by antibody VRC01.

    Tongqing Zhou;Ivelin Georgiev;Xueling Wu;Zhi Yong Yang

  • Human Immunodeficiency Virus Type 1 env Clones from Acute and Early Subtype B Infections for Standardized Assessments of Vaccine-Elicited Neutralizing Antibodies

    Ming Li;Feng Gao;John R. Mascola;Leonidas Stamatatos

  • Protection of Macaques against Pathogenic Simian/Human Immunodeficiency Virus 89.6PD by Passive Transfer of Neutralizing Antibodies

    John R. Mascola;Mark G. Lewis;Gabriela Stiegler;Dawn Harris

  • Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus

    Hua-Xin Liao;Rebecca Lynch;Tongqing Zhou;Feng Gao;Feng Gao

  • Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates.

    Kizzmekia S Corbett;Barbara Flynn;Kathryn E Foulds;Joseph R Francica

  • Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9

    Jason S. McLellan;Marie Pancera;Chris Carrico;Jason Gorman

  • Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals

    Johannes F. Scheid;Hugo Mouquet;Niklas Feldhahn;Michael S. Seaman

  • Broad and potent neutralization of HIV-1 by a gp41-specific human antibody

    Jinghe Huang;Gilad Ofek;Leo Laub;Mark K. Louder

  • Human skin Langerhans cells are targets of dengue virus infection.

    Shuenn-Jue L. Wu;Geraldine Grouard-Vogel;Wellington Sun;John R. Mascola

  • Structure and immune recognition of trimeric pre-fusion HIV-1 Env

    Marie Pancera;Tongqing Zhou;Aliaksandr Druz;Ivelin S. Georgiev

  • Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies.

    Nicole A. Doria-Rose;Chaim A. Schramm;Jason Gorman;Penny L. Moore

  • Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination.

    Alicia T. Widge;Nadine G. Rouphael;Lisa A. Jackson;Evan J. Anderson

  • Hemagglutinin-stem nanoparticles generate heterosubtypic influenza protection

    Hadi M. Yassine;Jeffrey C. Boyington;Patrick M. McTamney;Patrick M. McTamney;Chih Jen Wei;Chih Jen Wei

  • Tiered categorization of a diverse panel of HIV-1 Env pseudoviruses for assessment of neutralizing antibodies.

    Michael S. Seaman;Holly Janes;Natalie Hawkins;Lauren E. Grandpre

  • Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19.

    Nicole Doria-Rose;Mehul S. Suthar;Mat Makowski;Sarah O’Connell

  • Increased Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7 to Antibody Neutralization

    Pengfei Wang;Manoj S Nair;Lihong Liu;Sho Iketani;Sho Iketani

Frequent Co-Authors

Peter D. Kwong
Peter D. Kwong Columbia University Medical Center
Gary J. Nabel
Gary J. Nabel ModeX Therapeutics
Barney S. Graham
Barney S. Graham Morehouse School of Medicine
Mark K. Louder
Mark K. Louder National Institute of Allergy and Infectious Diseases
Sijy O'Dell
Sijy O'Dell National Institute of Allergy and Infectious Diseases
Robert T. Bailer
Robert T. Bailer National Institute of Allergy and Infectious Diseases
Richard T. Wyatt
Richard T. Wyatt Scripps Research Institute
David C. Montefiori
David C. Montefiori Duke University
Nicole A. Doria-Rose
Nicole A. Doria-Rose National Institute of Allergy and Infectious Diseases
Tongqing Zhou
Tongqing Zhou National Institutes of Health

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For those interested in immunology, pursuing related healthcare degrees can expand career opportunities significantly. Many professionals start with accelerated nursing pathways before specializing. For example, exploring an acnp programs can provide advanced clinical skills tailored to acute care, ideal for working with complex immunological conditions.

Individuals aiming to fast-track their nursing career might consider a nurse practitioner accelerated program. These intensive tracks help qualified nurses gain advanced practice credentials swiftly, supporting roles in immunology-related patient care and research.

For those without a nursing background, the best online rn programs for non nurses offer accessible entry points into nursing. These programs provide the foundational knowledge needed for clinical roles and further specialization in immunological science.

Additionally, the easiest absn to get into can be a practical choice for quickly transitioning into nursing practice. Success in these accelerated programs can pave the way to careers that intersect with immunology, such as infection control and immunotherapy nursing.

Best Scientists Citing John R. Mascola

Trending Scientists

Recently Published Articles